SCHEMBL316124

SCHEMBL316124

ONC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 5/20 0.55
KIF11 P52732 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
ALDH1A1 P00352 3/20 0.41
TSHR P16473 2/20 0.41
IDO1 P14902 2/20 0.41
CYP1A2 P05177 2/20 0.39
ALOX15 P16050 1/20 0.39
ESR1 P03372 2/20 0.37
ESR2 Q92731 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10292685 0.81 CA4 (0.48) KCNN4KIF11ALDH1A1CYP1A2CYP2C19
SCHEMBL191706 0.78 KCNN4 (0.52) KCNN4KIF11HDAC3HDAC4HDAC1
SCHEMBL21839329 0.75 KCNN4 (0.60) KCNN4KIF11HDAC3HDAC4HDAC1
SCHEMBL2363005 0.75 KCNN4 (0.60) KCNN4KIF11HDAC3HDAC4HDAC1
SCHEMBL9048029 0.74 HDAC3 (0.41) KCNN4HDAC3HDAC4HDAC1HDAC7
Ammonia Solution, Strong SCHEMBL28866362 0.73 KCNN4 (0.57) KCNN4KIF11HDAC3HDAC4HDAC1
SCHEMBL10933187 0.72 HDAC3 (0.50) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL22200647 0.72 TSHR (0.50) KCNN4KIF11HDAC3HDAC4HDAC1
SCHEMBL7007899 0.71 KCNN4 (0.48) KCNN4KIF11HDAC3HDAC4HDAC1
SCHEMBL9867906 0.71 KCNN4 (0.55) KCNN4KIF11HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378186-B2 Inhibitors of meprin α and β VIVORYON THERAPEUTICS N.V. (DE) 2025-08-05 US disclosed
EP-3967679-B1 NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA VIVORYON THERAPEUTICS AG (DE) 2025-02-19 EP disclosed
US-20250011333-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2025-01-09 US disclosed
CN-114507175-B Novel inhibitors of hypnotins alpha and beta 维沃里翁治疗股份有限公司 2024-10-01 CN disclosed
WO-2023172889-A1 USE OF CHEMICAL EPIGENETIC MODIFIERS TO MODULATE GENE EXPRESSION THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2023-09-14 WO disclosed
CN-114507175-A Novel inhibitors of hypnotic proteins alpha and beta 维沃里翁治疗股份有限公司 2022-05-17 CN disclosed
EP-3967679-A1 NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA Vivoryon Therapeutics AG (DE) 2022-03-16 EP disclosed
CN-109195947-B Novel inhibitors of hypnotic proteins alpha and beta 维沃里翁治疗股份有限公司 2022-03-04 CN disclosed
EP-3911645-A1 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE Université de Lille (FR) 2021-11-24 EP disclosed
EP-3445744-B1 NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA VIVORYON THERAPEUTICS AG (DE) 2021-10-06 EP disclosed
US-6489320-B1 NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND BENZOXAPINONE FOR TREATMENT OF HIV INFECTION BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-12-03 US disclosed
EP-1259499-A1 THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2002062290-A2 HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-15 WO disclosed
EP-1140895-A2 THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
WO-2001060808-A1 THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed
US-6140320-A FOR TREATING HIV(HUMAN IMMUNODEFICIENCY VIRUS) INFECTIONS DUPONT PHARMACEUTICALS COMPANY (US) 2000-10-31 US disclosed
WO-2000040576-A2 THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-13 WO disclosed
EP-1009742-A1 5,5-DISUBSTITUTED-1,5-DIHYDRO-4,1-BENZOXAZEPIN-2(3H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS Du Pont Pharmaceuticals Company (US) 2000-06-21 EP disclosed
WO-1999011635-A1 5,5-DISUBSTITUTED-1,5-DIHYDRO-4,1-BENZOXAZEPIN-2(3H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1999-03-11 WO disclosed
EP-0467844-A2 Prevention of oxidation in petrochemical extraction solvents CIBA-GEIGY AG (CH) 1992-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011333-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS MAP3K5, MAP3K9, MAP4K2 KCNN4 2752/4885KIF11 738/4885HDAC3 1749/4885
US-12378186-B2 Inhibitors of meprin α and β MEP1A, MEP1B, CAPRIN1 KCNN4 4492/4885KIF11 4362/4885HDAC3 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.